Skip to main content
. 2021 Apr 24;21:381. doi: 10.1186/s12879-021-06086-8

Table 3.

Clinical features, drug susceptibility and treatment outcome for a subgroup of 12 female patients with non-tuberculous mycobacterial disease

Pat/N Age (years) Site symptoms CXR- Finding Co-morbidities NTM-specie DST Profile TM Regimen Follow-up AFB smears and cultures TM duration TM outcome
2 M 4 M 6 M 9 M End of TM
1 20 Pul F, WL, PC, CP BL/FCD None MAC CLR, MXF, AMK EHR, CLR, AMK (6 M) P/P P/P N/NG N/NG N/NG 18 M Cured
2 50 Pul F, WL, PC, HM BL/FCD CLD, DM MAC CLR, MXF, AMK EHR, CLR, AMK (6 M) P/P P/P N/NG N/NG N/NG 18 M Cured
3 64 Pul F, WL, PC BL/FCD DM MAC CLR, MXF, AMK,LZD EHR, CLR AMK (6 M) P/P P/P N/NG N/NG N/NG 18 M Cured
4 48 Pul F, HM, SOB LT/FCD None MAC CLR, MXF AMK(r)a EHR, CLR, P/P NA NA N/NG N/NG 18 M Cured
5 45 Pul F, WL, PC BL/FCD CLD, DM MAC CLR, MXF, AMK EHR, CLR, AMK (6 M) P/P P/P N/NG N/NG N/NG 18 M Cured
6 45 Pul F, WL, PC BL/FCD CLD MAC CLR, MXF, AMK EHR, CLR, AMK (6 M) P/P P/P N/NG N/NG N/NG 18 M Cured
7 54 Pul F, WL, PC, HM BL/FCD DM MAC CLR, MXF, AMK EHR, CLR, AMK (6 M) P/P P/P N/NG N/NG N/NG 18 M Cured
8 65 Pul F, WL, PC BL/FCD DM MAC CLR, MXF, AMK EHR, CLR, AMK (6 M) P/P P/P N/NG N/NG N/NG 18 M Cured
9 68 Pul/ LN F, WL, PC BL/FCD HCV+ MAC CLR, MXF, AMK EHR, CLR, AMK (6 M) P/P N/NG N/NG N/NG N/NG 18 M Cured
10 18 Pul F, WL, PC

BL/FCD

LT/PTX

 None M. abscessus MXF, LZD, CLR EHR+ CLR (6 M)-shifted to MXF+ LZD (3 M) P/P P/P P/P Expired – 8 M Died
11 65 Pul F, PC BL/FCD None M. abscessus MXF, LZD, CLR LZD, MXF AMK (3 M) P/P P/P P/P N/P NA 12 M LTFUP
12 32 Pul F, WL, PC LT/FCD None M. abscessus MXF, LZD, CLR

MXF, LZD

CLR (2 M)

 P/P P/P N/NG N/NG N/NG 18 M Cured

Pat patient, N number, CXR chest X-ray, NTM Non-tuberculous mycobacteria, DST Drug susceptibility testing, TM treatment, M month, Pul pulmonary, LN Lymph node, F Fever, WL Weight loss, PC Productive cough, CP Chest pain, SOB Shortness of breath, HM Hemoptysis, BL Bilateral, FCD Fibro-cavitary disease, LT Left, PTX Pneumothorax, CLD Chronic liver disease, DM Diabetes mellitus, HCV Hepatitis C virus, MAC Mycobacterium avium complex, CLR Clarithromycin, MXF Moxifloxacin, AMK Amikacin, LZD Linezolid, EHR Ethambutol + isoniazid + rifampicin, r Resistant, aresistant to amikacin (patient-4). P Positive, N Negative, NG No growth, NA Not available, LTFUP Lost to follow-up